1. Home
  2. QLYS vs BLCO Comparison

QLYS vs BLCO Comparison

Compare QLYS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qualys Inc.

QLYS

Qualys Inc.

HOLD

Current Price

$130.90

Market Cap

5.5B

Sector

Technology

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.56

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QLYS
BLCO
Founded
1999
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Ophthalmic Goods
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.0B
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
QLYS
BLCO
Price
$130.90
$16.56
Analyst Decision
Hold
Hold
Analyst Count
15
14
Target Price
$139.43
$17.31
AVG Volume (30 Days)
416.5K
334.3K
Earning Date
02-05-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
13.91
N/A
EPS
5.16
N/A
Revenue
$653,034,000.00
$4,976,000,000.00
Revenue This Year
$12.00
$8.06
Revenue Next Year
$7.68
$5.79
P/E Ratio
$25.40
N/A
Revenue Growth
10.13
6.23
52 Week Low
$112.61
$10.45
52 Week High
$155.47
$18.55

Technical Indicators

Market Signals
Indicator
QLYS
BLCO
Relative Strength Index (RSI) 30.31 48.64
Support Level $131.00 $16.94
Resistance Level $140.74 $17.26
Average True Range (ATR) 3.85 0.31
MACD -1.79 -0.07
Stochastic Oscillator 6.78 2.74

Price Performance

Historical Comparison
QLYS
BLCO

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: